CSPC PHARMA (01093) announced that its developed product, Injectable Paclitaxel Albumin Nanoparticles (Instant Type) (SYHX2011G1), has received approval from the U.S. Food and Drug Administration (FDA) to commence clinical trials in the United States. Breast cancer is the most common malignant tumor among women globally, posing a serious threat to women's health. Taxanes are among the most commonly used and effective cytotoxic chemotherapy drugs for treating advanced breast cancer. Whether used as monotherapy or in combination regimens, they have demonstrated significant survival benefits compared to other types of chemotherapy agents. This product is a new-generation innovative nano-formulation developed using proprietary technology and has the potential to become the world's first instant albumin-bound paclitaxel preparation. The approved clinical indication is for the treatment of metastatic breast cancer that has failed combination chemotherapy or breast cancer that has recurred within six months after adjuvant chemotherapy. The approval for this clinical trial will further enrich the company's internationally positioned product pipeline and enhance its global competitiveness.